>>> US Gapping down

Gapping down

In reaction to disappointing earnings/guidance:

FLDM -29.2%, SUPN -28.3% (also reports Phase III P301 trial in patients 6 to 11 years old did not meet primary endpoint), PLT -26.2%, VGR -24.2% (announces decision to reduce quarterly cash dividend to $0.20/share, effective in the first quarter of 2020), AMRX -23%, SWIR -18.9%, WW -15.5%, LL -14.7%, ATUS -14.1%, GWPH -12.5%, VG -12.5%, FANG -12.3%, MTCH -11.7%, WLL -10.4%, FRGI -9.6%, GTE -9.4%, CENX -8.5%, LTHM -7%, HUBS -6.5%, RRGB -6.2%, COHR -5.2%, VMC -5%, MODN -4.9%, RRR -4.9%, MCHP -4.5%, OPK -4.5%, ELAN -3.4%, FATE -3.2%, CPS -3.1%, SMG -3.1%, CPRI -2.9%, KELYA -2.9%, BR -2.8%, NEWR -2.7%, PRMW -2.7%, ABUS -2.7%, CARS -2.5%, OMI -2.3%, VER -2%, PE -1.9%, BEAT -1.7%, RGNX -1.6%, TWO -1.5%, AKCA -1.3%, IPHS -1.3%, PRGO -1.2%, ESPR -1.2%, MDGL -1%

Other news:

MNK -4.5% (discloses August receipt of SEC subpoena in 10-Q)

ZYME -1.3% (enters into $75 mln Open Market Sale Agreement concurrent with automatic shelf registration statement )

MPW -0.9% (prices 50 mln share common stock offering at $18.50 per share)

ARGO -0.6% (names Kevin Rehnberg Interim CEO after retirement of Mark Watson effective immediately)

Analyst comments:

CTL -3.1% (downgraded to Sell from Neutral at Guggenheim)

GRPN -2% (downgraded to Underweight from Neutral at JP Morgan)

MOS -0.8% (downgraded to Neutral from Overweight at JP Morgan)